DCGI approves Nintedanib for the treatment of systemic sclerosis-associated interstitial lung…
Approval is based on the SENSCIS study which showed Nintedanib slows the loss of pulmonary function in people living with systemic…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.